News

AL-408 has been proven to have potent neuroprotective effects in a number of in vitro and in vivo models of neurotoxicity, the data from pre-clinical studies says. In

Aptiv Solutions will manage the Galena Phase 3 trial, PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment). The

Lodotra, which is currently approved for marketing in 16 European countries is a modified (delayed)-release formulation of low-dose prednisone. Circadian Administration of Prednisone in RA (CAPRA-2), 12-week, double-blind,

According to the arm Phase II study which comprised 126 patients receiving BIBF 1120 as first-line treatment in combination with mFOLFOX6 showed a median progression-free survival of 10.6

Under the deal, both the firms will focus on developing three of Proximagen’s programmes, with the aim of identifying novel innovative therapies for serious diseases such as epilepsy,

The grant allows both the companies to jointly develop a preclinical program on a potential new treatment for stroke patients. The program is aimed to deliver NeuroVive’s cyclosporin

The decision was made because Astellas found it was difficult to find a partner for the Phase III clinical development and commercialization of darexaban. The company also considered

The NoA includes claims directed to the use of Zertane with a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors commonly used for the treatment of ED

The first grant entitled ‘In Vitro Tools for Preclinical Analysis of Cognitive Therapies for Schizophrenia’ for the development of preclinical assays that accurately model human cognitive processes. Galenea